RecruitingPhase 1

Study of MAR002 in Healthy Men

United States45 participantsStarted 2025-08-11

Plain-language summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Who can participate

Age range18 Years – 40 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willingness to provide written informed consent
✓. Age 18 to 40
✓. Weight 55 to 95 kg
✓. Body mass index (BMI) 18 to 30 kg/m2
✓. Healthy men

Exclusion criteria

✕. History of hypersensitivity to monoclonal antibodies or study drug
✕. Participation in any other investigational drug study
✕. History of cancer
✕. Recent acute illness
✕. Positive test for HIV, hepatitis B/C
✕. History of substance abuse or nicotine use
✕. Recent blood donation
✕. History of pituitary disorder

What they're measuring

Number of participants with TEAEs (treatment-emergent adverse events)

Timeframe: From first dose of study drug through final End of Study/Early Termination Visit. End of Study is Day 64 for Cohorts 1 and 2; End of Study is day 169 for Cohorts 3, 4, 5, and 6.

Trial details

NCT IDNCT07195175

SponsorMarea Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Andrew Lane

415-766-3610 mar-201-info@mareatx.com

View on ClinicalTrials.gov More Acromegaly trials